Vulvovaginal Candidiasis Treatment Market Growth, Share, Scope and Competitive Analysis 2022-2032


Vulvovaginal Candidiasis Treatment Market Growth, Share, Scope and Competitive Analysis 2022-2032: SPER Market Research

 Category : Pharmaceutical

 Published: Dec-2022
 Author: SPER Analyst

Vulvovaginal Candidiasis Treatment Market is projected to be worth USD 1.62 billion by 2032 and is anticipated to surge at a CAGR of 4.61%.

A fungal infection of the vulva and vagina caused by an infestation of the fungus Candida is known as vulvovaginal candidiasis, or vaginal yeast infection. In addition to thick, white, odorless discharge, the disease's most prevalent symptoms include vaginal itching, burning, and pain. Additional symptoms include pain during urination or intercourse, vulva redness and swelling, overall genital discomfort, etc. Women may occasionally suffer from chronic illnesses or recurrent infections, which can have a serious negative impact on their quality of life. A physical examination by a healthcare professional, including a pelvic exam and testing on a vaginal discharge swab, is usually required to diagnose this illness. 

Global Vulvovaginal Candidiasis Treatment Market Driving Factors and Challenges
Increasing R&D expenditures and diversifying product offerings: Numerous safe and efficient antifungal medicines have been introduced to the market. Itraconazole, fluconazole, and terbinafine are a few of the potent antifungal medications on the market. The pharmaceutical companies are investing more in R&D with the goal of diversifying their line of anti-infective medications. The majority of industry participants are concentrating on the creation of potent therapeutic drugs that can treat fungal diseases such vulvovaginal candidiasis in people with weakened immune systems. Adverse consequences of using medications like fluconazole: Antifungal drugs like fluconazole are administered to treat fungal infections of the candida, including vulvovaginal candidiasis. When fluconazole is used with other medications such as blood thinners, antibiotics, sedatives, diuretics, antiseizure drugs, and other prescriptions, there may be drug interactions. Additionally, those with liver illnesses or any other ailments that might result in eating such situations should heed the many cautions specified on the prescriptions. This is the main restraining factor for the market.

Impact of COVID-19 on Global Vulvovaginal Candidiasis Treatment Market
The global spread of the new coronavirus has had a little effect on the market for vulvovaginal candidiasis treatments. Due to the increasing incidence of vulvovaginal candidiasis among COVID-19 patients, there was a significant market need for medications to treat the condition. This is a result of an increase in bloodstream infections and illnesses related to healthcare, particularly among hospital admitted patients. Because of all these factors, the market for vulvovaginal candidiasis rebounded swiftly from the first quarter of 2020 and is expected to continue growing. 

Global Vulvovaginal Candidiasis Treatment Market Key Players:
The market study provides market data by competitive landscape, revenue analysis, market segments and detailed analysis of key market players such as Alembic Pharmaceuticals Limited, Accord Healthcare Ltd., Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Basilea Pharmaceuticals Ltd., Cadila Pharmaceuticals, Dr Reddy’s Laboratories Ltd., Grupo Ferrer Internacional S.A, Glenmark Pharmaceuticals Ltd., Zydus Cadila

Global Vulvovaginal Candidiasis Treatment Market Segmentation:

By Type: Based on the Type, Global Vulvovaginal Candidiasis Treatment Market is segmented as; Acute Vulvovaginal Candidiasis, Recurrent Vulvovaginal Candidiasis, Severe Vulvovaginal Candidiasis, Non-Albicans Vulvovaginal Candidiasis.

By Drug Class: Based on the Drug Class, Global Vulvovaginal Candidiasis Treatment Market is segmented as; Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, Others

By Route of Administration: Based on the Route of Administration, Global Vulvovaginal Candidiasis Treatment Market is segmented as; Oral, Intravenous, Topical

By Distribution Channel: Based on the Distribution Channel, Global Vulvovaginal Candidiasis Treatment Market is segmented as; Hospital Pharmacy, Retail Pharmacy, Online Pharmacy.

By Region: This research also includes data for North America, Asia-Pacific, Latin America, Middle East & Africa and Europe. 

This study also encompasses various drivers and restraining factors of this market for the forecast period. Various growth opportunities are also discussed in the report.

Join Our SPER Panel

Our Global Clients

Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Johnson & Johnson


Market Research

We are the leading, full-service global market research and consulting company.

iso-1 iso-1 iso-1 ESOMAR
Secure Payments
SPER Payment Options
Contact HR

 [email protected]